Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 11/20 | 1.00 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1985993 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL1988210 | 0.90 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL1986232 | 0.90 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL1351184 | 0.90 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL1987786 | 0.90 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL29352985 | 0.90 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL1987780 | 0.90 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL1351190 | 0.90 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL12465624 | 0.90 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL1986909 | 0.89 | HSP90AA1 (0.88) | HSP90AA1HSP90AB1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049781-A1 | HSP90 INHIBITOR COMBINATIONS | NOVARTIS AG (CH) | 2017-02-23 | — | — | US | claimed |
| US-20150209362-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | claimed |
| US-20140328834-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | NOVARTIS AG (CH) | 2014-11-06 | — | — | US | claimed |
| US-20140242088-A1 | Hsp90 inhibitor combinations | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | claimed |
| EP-2572709-A1 | HSP90 inhibitors for therapeutic treatment | Novartis AG (CH) | 2013-03-27 | — | — | EP | claimed |
| US-20130045983-A1 | HSP90 INHIBITORS FOR THERAPEUTIC TREATMENT | NOVARTIS AG (CH) | 2013-02-21 | — | — | US | claimed |
| US-20120219550-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | NOVARTIS AG (CH) | 2012-08-30 | — | — | US | claimed |
| EP-2370079-A2 | HSP90 INHIBITORS FOR THERAPEUTIC TREATMENT | Novartis AG (CH) | 2011-10-05 | — | — | EP | claimed |
| EP-2370076-A2 | PHARMACEUTICAL COMBINATION COMPRISING A HSP 90 INHIBITOR AND A MTOR INHIBITOR | Novartis AG (CH) | 2011-10-05 | — | — | EP | claimed |
| US-20110236379-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | NOVARTIS AG (CH) | 2011-09-29 | — | — | US | claimed |
| US-20110230444-A1 | PHARMACEUTICAL COMBINATION COMPRISING A HSP 90 INHIBITOR AND A MTOR INHIBITOR | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | claimed |
| US-20110230499-A1 | HSP90 INHIBITORS FOR THERAPEUTIC TREATMENT | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | claimed |
| EP-1928875-B1 | 2-amino-7,8-dihydro-6H-pyrido(4,3-d)pyrimidin-5-ones, process for their preparation and pharmaceutical compositions containing the same | NOVARTIS AG (CH) | 2011-06-29 | — | — | EP | claimed |
| WO-2010060937-A2 | HSP90 INHIBITOR COMBINATIONS | NOVARTIS AG (CH) | 2010-06-03 | — | — | WO | claimed |
| WO-2010060940-A2 | HSP90 INHIBITORS FOR THERAPEUTIC TREATMENT | NOVARTIS AG (CH) | 2010-06-03 | — | — | WO | claimed |
| US-7671059-B2 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | NOVARTIS AG (CH) | 2010-03-02 | — | — | US | claimed |
| US-20170049781-A1 | HSP90 INHIBITOR COMBINATIONS | NOVARTIS AG (CH) | 2017-02-23 | — | — | US | disclosed |
| EP-2370076-B1 | Pharmaceutical combination comprising a Hsp 90 inhibitor and a mTOR inhibitor | NOVARTIS AG (CH) | 2017-01-04 | — | — | EP | disclosed |
| WO-2007041362-A1 | 2-AMINO-7,8-DIHYDRO-6H-PYRIDO[4,3-D] PYRIMIDIN-5-ONES | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041362-A1 | 2-AMINO-7,8-DIHYDRO-6H-PYRIDO[4,3-D] PYRIMIDIN-5-ONES | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230499-A1 | HSP90 INHIBITORS FOR THERAPEUTIC TREATMENT | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885TRAP1 20/4885 |
| US-20110230444-A1 | PHARMACEUTICAL COMBINATION COMPRISING A HSP 90 INHIBITOR AND A MTOR INHIBITOR | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885TRAP1 19/4885 |
| US-20140328834-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 5/4885HSP90AB1 2/4885TRAP1 40/4885 |
| US-20150209362-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 5/4885HSP90AB1 2/4885TRAP1 40/4885 |
| US-20130045983-A1 | HSP90 INHIBITORS FOR THERAPEUTIC TREATMENT | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885TRAP1 22/4885 |
| US-20110236379-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 5/4885HSP90AB1 2/4885TRAP1 40/4885 |
| US-20140242088-A1 | Hsp90 inhibitor combinations | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885TRAP1 14/4885 |
| US-20170049781-A1 | HSP90 INHIBITOR COMBINATIONS | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885TRAP1 12/4885 |
| US-20120219550-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 5/4885HSP90AB1 2/4885TRAP1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.